Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ platform. By using AI, we can review and optimize drug candidates at a much greater pace than ever before. The Company has established a pipeline of distinctive DNA-damage response inhibitors to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners.
For more information, please visit: https://www.rakovinatherapeutics.com/
Corporate Speaker
Jeffrey Bacha , BSc, MBA
Executive Chairman
Mr. Bacha has been involved in pharmaceutical research and corporate development for more than 25 years, serving as a member of the executive leadership team for multiple companies. He is the founder and Chief Executive Officer of Edison Oncology Holding Corp., a private corporation that sold certain assets to establish Rakovina Therapeutics. Prior to founding Edison Oncology, Mr. Bacha co-founded Kintara Therapeutics (NASDAQ: KTRA, formerly DelMar Pharmaceuticals) with Dr. Dennis Brown, serving as Chairman and CEO during the company’s growth, including advancing its lead product candidate to pivotal Phase III clinical trials and achieving a NASDAQ listing. He has also served as founding CFO of XBiotech, Inc. (NASDAQ: XBIT), founding CEO of Inimex Pharmaceuticals, and Vice President of Corporate Development at Inflazyme Corp. (TSX: IZP).
Disclaimer: NAI is being compensated for this content. Materials contained in this content are for information purposes only and is not intended to constitute an offering of securities in any jurisdiction. Nothing on this content should be construed as an offer, solicitation or recommendation to buy or sell products or securities.
Music: pixabay
【Stay Connected! 】
Email Subscription: https://sourl.cn/TkSQJk
Website: https://nai500.com
Twitter: https://twitter.com/NAI500
LinkedIn: https://www.linkedin.com/company/nai-interactive-ltd/
Facebook: https://www.facebook.com/naigcff/
Join us at an upcoming event! http://www.gcff.ca/
Copyright © 2025 NAI Interactive Ltd. All rights reserved.
For more information, please visit: https://www.rakovinatherapeutics.com/
Corporate Speaker
Jeffrey Bacha , BSc, MBA
Executive Chairman
Mr. Bacha has been involved in pharmaceutical research and corporate development for more than 25 years, serving as a member of the executive leadership team for multiple companies. He is the founder and Chief Executive Officer of Edison Oncology Holding Corp., a private corporation that sold certain assets to establish Rakovina Therapeutics. Prior to founding Edison Oncology, Mr. Bacha co-founded Kintara Therapeutics (NASDAQ: KTRA, formerly DelMar Pharmaceuticals) with Dr. Dennis Brown, serving as Chairman and CEO during the company’s growth, including advancing its lead product candidate to pivotal Phase III clinical trials and achieving a NASDAQ listing. He has also served as founding CFO of XBiotech, Inc. (NASDAQ: XBIT), founding CEO of Inimex Pharmaceuticals, and Vice President of Corporate Development at Inflazyme Corp. (TSX: IZP).
Disclaimer: NAI is being compensated for this content. Materials contained in this content are for information purposes only and is not intended to constitute an offering of securities in any jurisdiction. Nothing on this content should be construed as an offer, solicitation or recommendation to buy or sell products or securities.
Music: pixabay
【Stay Connected! 】
Email Subscription: https://sourl.cn/TkSQJk
Website: https://nai500.com
Twitter: https://twitter.com/NAI500
LinkedIn: https://www.linkedin.com/company/nai-interactive-ltd/
Facebook: https://www.facebook.com/naigcff/
Join us at an upcoming event! http://www.gcff.ca/
Copyright © 2025 NAI Interactive Ltd. All rights reserved.
- Category
- Artificial Intelligence
Comments